CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Asarina Pharma AB (publ) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Asarina Pharma AB (publ)
Karolinska Institutet Science Park
Fogdevreten 2
Phone: +46 852484482p:+46 852484482 SOLNA, 171 65  Sweden
On 8/21/2024, the Board of Directors of Asarina Pharma AB (publ) announced its decision to place the Company into a Voluntary Liquidation
The Board of Directors intend to propose that the Liquidation date be set to 12/1/2024
This company is no longer actively traded on any major stock exchange.
Business Summary
Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of women’s health. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer PeterNordkild
Independent Chairman of the Board Paulde Potocki 60 1/1/2018 1/1/2018
Chief Executive Officer PeterNordkild 67 3/1/2017 3/1/2017
8 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 22,641,409 (As of 12/31/2023)
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024